Proteins consisting of one, two or four copies of the amino acid sequence 137 to 162, which contains the major immunogenic site of VP1 of foot-and-mouth disease virus, attached to the N-terminus of fl-galactosidase have been expressed in Escherichia coli cells. In guinea-pigs the protein containing one copy (P71) of the viral determinant elicited only low levels of neutralizing antibody whereas protective levels were elicited by the proteins containing two (P72) or four (P74) copies of the determinant. Single inoculations of the P72 and P74 proteins containing as little as 2 ~tg or 0-8 gg of peptide respectively were sufficient to protect all the animals against challenge infection. Moreover, the equivalent of 40 gg of peptide in P74 protected pigs against challenge infection after one inoculation.
INTRODUCTION
Foot-and-mouth disease is a major cause of economic loss to the livestock industry. It is caused by a picornavirus whose structural and antigenic properties have been studied extensively over many years with the objective of improving the vaccines which are used to control the disease in many parts of the world (for review, see Brown, 1985) . Present day vaccines are produced by inactivating, usually with an imine, virus grown in surviving bovine tongue epithelial fragments (Frenkel, 1947) or in the baby hamster kidney cell line BHK-21 (Macpherson & Stoker, 1962; Mowat & Chapman, 1962 ). The inactivated virus is then injected either after adsorption on to AI(OH) 3 gel or after emulsification with a mineral oil.
While the success of these vaccines in controlling the disease is widely recognized, the disadvantages of a product which must be stored and transported at refrigerator temperatures (the so-called cold chain) and which can also cause anaphylaxis have led workers to seek alternative methods for preparing vaccines. Studies on the structure of the foot-and-mouth disease virus (FMDV) particle showed that the protein VP 1 contains the immunodominant site (Wild et al., 1969) and this supposition was confirmed by the demonstration that the isolated protein elicited neutralizing antibody in experimental animals and in pigs and cattle (Laporte et al., 1973 ; Bachrach et al., 1975) . However, the immunogenicity of the isolated protein was very low (<0-01 ~) compared with that of the intact virus particle. Similarly the same protein expressed in Escherichia coli cells also had very low activity (Kleid et al., 1981) . These results were assumed to be due to the altered configuration which the protein takes up when it does not form part of the architecture of the virus.
The observation that fragments of VPI would elicit neutralizing antibody (Kaaden et al., 1977) led to a detailed investigation of the location of the immunogenic site once the virus RNA had been mapped (Sangar et al., 1977) and sequenced (Kurz et al., 1981) . The studies identified the amino acid sequence 141 to 160 as an immunodominant region of the protein (Strohmaier et 0000-7969 M. P. BROEKHUIJSEN AND OTHERS al., 1982) and synthetic peptides corresponding to this region have been investigated in some detail (Bittle et aL, 1982; Pfaff et al., 1982; Francis et al., 1985a) . Despite their greater immunogenic activity compared with that of the entire protein, the peptides still had a lower activity than the intact virus particle. This has led to studies on the presentation of the peptide so that its activity is enhanced (Francis et al., 1985b; 1987a, b) . The peptide alone is immunogenic and coupling it to different carrier protein molecules does not lead to an improved response in guinea-pigs. Indeed in some instances the activity of the coupled peptide is lower than that of the uncoupled molecule (M. J. Francis et al., unpublished data) . In their paper describing the immunogenic activity of the 141 to 160 region of VP1, Bittle et al. (1982) also showed that the 200 to 213 region, which was a site predicted by Strohmaier et al. (1982) to be immunogenic, elicited neutralizing antibodies in guinea-pigs, although at a much lower level than the 141 to 160 sequence. The potential importance of the 200 to 213 sequence in enhancing the response to the 141 to 160 sequence was indicated by the serological evidence with a chemically synthesized peptide containing both sequences. Such a peptide was more reactive with neutralizing monoclonal antibodies against the intact virus than either sequence alone (Parry et al., 1985) . Moreover, a similar peptide was shown by DiMarchi et al. (1986) to be more immunogenic in cattle than the major site alone.
The use of peptide sequences fused to bacterial proteins as immunogens has the potential advantage of a completely uniform and defined structure compared with the uncharacterized and variable nature of peptide-carrier conjugates prepared by chemical cross-linking. This approach has been used independently by Broekhuijsen et al. (1986a) and Winther et al. (1986) . Both groups used an expression vector into which the genes coding for amino acids 137 to 162 or 142 to 160 of the viral protein were fused to the gene coding for fl-galactosidase and expressed in E. coli cells, fl-Galactosidase was chosen because it had been shown that antibodies are formed against foreign proteins which are located at the amino terminus of such fusion proteins. Moreover, there is now information on the location of the antigenic sites on fl-galactosidase molecules which are recognized by helper T cells (Krzych et al., 1982 : Manca et al., 1985 .
In preliminary experiments in rabbits we have shown that proteins consisting of flgalactosidase plus two or four copies of the sequence 137 to 162 situated at the N terminus elicit higher levels of virus-specific antibody than the protein containing only one copy of the peptide (Broekhuijsen et al., 1986b) . Furthermore, Kleid et al. (1985) have provided evidence that two copies of the determinant, expressed in E. coli as a fusion protein with TrpLE, elicited high levels of neutralizing antibody in cattle and protected them from infection. However, the direct comparison with the fusion protein containing a single copy of the determinant was not made.
This paper provides a more comprehensive study of the relative potencies of the fusion proteins containing one, two or four copies of the sequence 137 to 162. It demonstrates that a fusion protein with two or four copies elicits high levels of neutralizing antibody and protects both guinea-pigs and pigs against infection.
METHODS

Construction of expression plasmids.
The construction of plasmids pM01-71, p M01-72 and pM01-74 has been described before (Broekhuijsen et al., 1986a, b) . These plasmids encode fusion proteins P71, P72 and P74, containing one, two and four copies of amino acids 137 to 162 from VP1 of FMDV, type O1 BFS, fused to the N terminus of/~-galactosidase. Plasmid pM0 l-81 encodes fusion protein P8 l, which contains amino acids 137 to 162 and 199 to 213 from V P 1 fused to the N terminus of fl-galactosidase. The plasmid was obtained by insertion of a synthetic DNA molecule into the unique BamHI site of pM01-71 which is locatedbetween the VP1 and lacZ genes. The synthetic DNA of 66 bp, encoding amino acids 199 to 213 of VP1, was synthesized in one piece with BamHI-complementary ends. Insertion of this DNA into pM01-71 would restore only the BamHI site at the 3' side. The resulting plasmid pM01-81 was analysed by DNA sequence determination of the 199 to 213 encoding region.
Preparation of P71, P72, P74 and P81. The fusion proteins P71, P72, P74 and P81 were produced and purified as described by Broekhuijsen et al. (1986b) . A yield of 20 to 30 mg of fusion protein was usualy obtained from a bacterial culture of 6 1.
Animals. Female Dunkin-Hartley guinea-pigs, approximately 12 weeks old and weighing between 450 and 500 g were housed at the Animal Virus Research Institute, Pirbright, U.K. Deutsche Londrasse pigs approximately 10 to 12 weeks old were housed at Impfstoffwerk Wellcome GmbH, Burgwedel, F.R.G.
Injection of animals.
All animals were inoculated intramuscularly (i.m.) using a 2 ml dose for pigs and a 1 ml dose for guinea-pigs. Further details of antigen dose, adjuvants and sampling schedules for individual experiments are given in the Results section.
Challenge. Guinea-pigs were injected intradermally into the left hind footpad with a 0.02 ml dose of O1 Kaufbeuren virus containing 500 IDs0. Animals were examined daily for 7 days and those with no lesions or lesions only at the injection site were regarded as protected.
Pigs were injected with 30000 IDso of O~ Kaufbeuren virus into each of the two heel bulbs on the right fore foot. Inspections for the development of local lesions were made over 7 days and pigs were classified as protected if lesions were totally absent from the injection site, the remaining three feet and the snout.
Neutralization assay. The neutralizing activity of serum samples against 100 TCIDs0 of virus was determined using a microneutralization test with IBRS2 cells (Francis & Black, 1983) . Each test was performed in duplicate and the results were recorded as the mean loglo reciprocal of the serum dilution that gave confluent cell sheets in 50% of the microplate wells (SNso).
ELISA. A modification of the indirect ELISA technique described by Voller & Bidwell (1976) was used to assay anti-peptide IgG responses. Briefly, microplates were coated overnight at room temperature with uncoupled 137 to 160 Cys synthetic peptide at a concentration of 2 gg/ml. The plates were washed and test serum samples at a range of doubling dilutions from 1 : 10 were added. After incubation for 1 h at 37 °C plates were washed and antiguinea-pig IgG-peroxidase conjugate was added. After a further hour at 37 °C the plates were washed and an enzyme substrate (0.04~ o-phenylenediamine with 0.004% hydrogen peroxide in phosphate~zitrate buffer) was added. The resulting colour development was stopped with 12-5~o sulphuric acid after 5 to 7 min and the absorbance at 492 nm was measured in a Titertek Multiskan (Flow Laboratories).
The A,,9 2 values obtained from doubling dilutions of post-inoculation samples were plotted against the log10 reciprocal antiserum dilution and the antibody titres were calculated by reference to a negative standard (a 1:10 dilution of pre-inoculation serum). The results reported are the means of two tests, using duplicate wells for each serum dilution in each test.
RESULTS
Response of guinea-pigs to the fusion proteins
Groups of four guinea-pigs were inoculated i.m. with 200 ~g of the four fusion proteins P71, P72, P74 and P81, containing approximately 5, 10, 20 and 5 gg respectively of the peptide 137 to 162. A fifth group received 5 gg of the chemically synthesized peptide 137 to 160 Cys. All preparations were emulsified 1 : 1 with incomplete Freund's adjuvant (IFA). The results of the experiments, which are summarized in Table 1 , show that the proteins containing two or four copies of the peptide sequence elicited a much greater response at 28 and 56 days, both of antipeptide and neutralizing antibody, than the protein containing only one copy of the peptide sequence. Moreover, all the animals that received P72 and P74 were protected at 56 days against intradermal challenge with 500 IDso0 of virus. None of the animals that received P71 or the chemically synthesized peptide were protected. Furthermore, the response to P81 was as poor as the response obtained with P71 in that it failed to evoke any detectable neutralizing antibody response, resulting in complete lack of protection at 56 days. The correlation between protection and level of neutralizing antibody in the serum at the time of challenge was again evident, in agreement with our previous work with chemically synthesized peptides (Francis et al., 1985a) .
In a second experiment, a range of concentrations, from 1000 to 8 gg, of P71, P72 and P74 emulsified with IFA were inoculated i.m. into groups each containing four guinea-pigs. The results in Table 2 show that as little as 8 Izg of the fusion proteins, containing 0.4 ~g of peptide for P72 and 0.8 p.g of peptide for P74, could provide protection against challenge infection although 40 gg of P72 containing 2 gg of peptide was required for protection of all the animals inoculated. The level of neutralizing antibody in the animals could be correlated with the amount of injected protein and was marginally greater in those animals which received P74. Once again all animals that received the single copy construct, P71, failed to produce detectable levels of neutralizing antibody and were not protected from challenge at 56 days.
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protein. However, the use of aluminium hydroxide as an adjuvant for P72 resulted in a reduced neutralizing antibody response and incomplete protection at 56 days.
Response of pigs to fusion protein P74
Four pigs were inoculated i.m. with a water-in-oil emulsion containing 400 ~g of fusion protein P74 per dose (equivalent to 40 ~tg 137 to 162 peptide). Sixty-six days later two of the animals, with the highest neutralizing antibody levels, were challenged with 30000 IDs0 of virus. The other two pigs were given a second inoculation and challenged 35 days later. The mean neutralizing antibody response is shown in Fig. 1 and protection data are given in Table 4 . Neutralizing antibody was detectable 7 days after inoculation and reached a plateau 28 days later. The second inoculation at 66 days produced a 10-fold increase in the levels of neutralizing antibody. The titres of between 2-0 to 2.8 loglo at the time of challenge, either after one or two inoculations, conferred complete protection.
DISCUSSION
The results described in this paper demonstrate clearly that proteins consisting of two or four copies of the peptide 137 to 162 fused to the N terminus of fl-galactosidase are highly immunogenic and are greatly superior to that containing a single copy of the peptide in eliciting anti-peptide and neutralizing antibody and in protecting against challenge infection. As little as 8 ~tg of the fusion proteins containing two (P72) or four (P74) copies of the peptide was sufficient to confer protection in guinea-pigs after one injection. Moreover, approximately 400 ~g of the protein P74 containing four copies of the peptide, equivalent to 40 ~tg of FMDV peptide, were sufficient to cortfer protection on pigs. These results, together with those described by Kleid et al. (1985) , provide good evidence that small amounts of the peptide, suitably presented, will confer immunity on the natural hosts. The choice of adjuvant is important since the results obtained using aluminium hydroxide were poor. Furthermore, the fusion protein could be freeze-dried prior to use with no deleterious effect on the response.
We can offer no definitive explanation for the enhanced response to the proteins containing the multiple copies of the peptides. Although it is possible that the new sequence created by the fusion of the two copies of 137 to 162 produces the enhanced effect, it seems more likely to us that the configuration of the multiple copies of the peptide may be the key factor in producing the greater response. Nuclear magnetic resonance or X-ray crystallographic studies may be required to provide the solution to this problem.
